Yes, and substantially
This early timing reflects how rapidly semaglutide begins altering your digestive system and appetite signaling pathways
Apr 8, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,805 views The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability
Ultimately, GLP-1based adjunct therapy in type 1 diabetes should be viewed as a personalized option rather than a standard treatment
Chandrasekaran, K
Needle gauge matters too: a finer needle (commonly 29-31 gauge for insulin syringes) reduces the mechanical stress placed on the solution as it passes through the needle bore compared to a larger-bore needle, and produces a smaller, cleaner puncture through the vial's rubber stopper, reducing the risk of coring small rubber fragments breaking off into the solution